HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical characteristics of immature T-type (negative E-rosette) acute lymphoblastic leukemia detected by LAU-A1 monoclonal antibody].

Abstract
Immature T-ALL is a newly defined subgroup of ALL in which the blasts lack the receptor for sheep erythrocytes (ER) and the usual T-cell markers, but express the 40 kDa pan-T surface antigen recognized by our monoclonal antibody LAU-A1. Patients with immature T-ALL represent 10% of all cases of adult ALL. Leukocyte counts are lower and spleen, liver and lymph node enlargement is less prominent, but mediastinal enlargement is more frequent than in mature (ER-positive) T-ALL. 7 patients with immature T-ALL (median age 42 years, range 13-73) were treated with intensified chemotherapy regimens, and only one 47-year-old female entered a short-lived complete remission. The overall survival of our patients was poor (median 7.5 months, with only one patient surviving at 15 months) and seemed not to be influenced by age. Our study indicates that immature T-ALL can only be accurately identified by the use of monoclonal antibodies recognizing the 40 kDa pan-T antigen, and that immature T-ALL is a separate disease entity typified by a poor prognosis.
AuthorsV von Fliedner, J P Grob, D Heumann, S Carrel, B Chapuis, M Fopp, P Imbach, F Cavalli, J P Mach
JournalSchweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 115 Issue 43 Pg. 1515-6 (Oct 26 1985) ISSN: 0036-7672 [Print] Switzerland
Vernacular TitleCaractéristiques cliniques des leucémies lymphoblastiques aiguës de type T immature (E-rosette négatif) détecté par l'anticorps monoclonal LAU-A1.
PMID3878589 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antibodies, Monoclonal
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal (immunology)
  • Humans
  • Leukemia, Lymphoid (immunology)
  • Middle Aged
  • Prognosis
  • T-Lymphocytes (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: